Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
about
Perspectives on menopause and women with HIVHIV infection and osteoporosisScreening for chronic comorbid diseases in people with HIV: the need for a strategic approachHIV: inflammation and boneOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesBone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialAgeing and inflammation in patients with HIV infection.HIV infection and bone disease.Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialShort-term bone loss in HIV-infected premenopausal womenLifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependencePer oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients.Incident fractures in HIV-infected individuals: a systematic review and meta-analysisBone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected womenInflammation, Immune Activation, and Antiretroviral Therapy in HIVAssociation between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.A challenge for the future: aging and HIV infection.Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy oBone disease in HIV infection: a practical review and recommendations for HIV care providers.Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study.Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infectionIncreased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIVCommentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss.Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.Racial differences in bone loss and relation to menopause among HIV-infected and uninfected women.Bone disease in HIV infection.Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adultsHigher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study.Bone health in HIV-infected children, adolescents and young adults: a systematic review.Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.
P2860
Q26772852-11A7E592-00B9-492B-9BE7-EA116576C6B1Q26853139-5EB618EA-50C6-405E-B676-B9300F6DE06DQ26866452-1648ADFC-811F-4413-A07C-9A6463D46F74Q27010898-CB34A1D8-665A-436D-8293-4377E37A0159Q27023352-C99496A8-1CEC-4956-83DB-ABF4B04249F9Q28476730-383F33EB-B9BB-4EA8-82FF-9B6BEBD1E09AQ28730855-F0B47CFD-1BF1-420B-BAF8-82096E28E76CQ30244296-718A55AE-FD04-4EBB-BA27-B6E739FCDAFFQ30249771-B16B7362-476F-486A-A36C-17E7BEEEA058Q31124706-36C05C6E-204D-4D6C-8698-0C9C3DCD1B93Q33604322-80FAD5AB-2850-430E-BF40-E3DED1D7094EQ33618567-0E15A453-95B9-4EE9-B755-E5119BD8AF0AQ33627227-B112F0D0-1FAD-4833-95F6-960392FB340DQ33643157-5570F8DA-E90C-4DEB-AC4E-DED615C85D6AQ33648297-AA4870E9-C50B-4187-97CD-FBFB86593833Q33665210-8C19C59B-5293-41B9-87A7-BC716FE31A27Q33736156-80EC1BBD-D378-49A5-AC0B-2AF7DB6D21DCQ33912595-AEC4A384-D8F6-45C2-B51C-FCA9C8114D50Q34153519-B790819B-F9DB-49A2-B0DE-372C25C531E5Q34168353-9857BF16-9CE7-4A18-9E6C-61CDD3F08E1DQ34264297-796AEA3D-2507-4B93-B0DD-0771697057B0Q34478840-A84655AE-C8EC-4C2E-BE20-71B220EA84B5Q34786514-AB01D33C-A48D-4157-95FC-1D2AF3210F4BQ34796517-3676D5A5-5578-4EBF-B405-ADF631876E6EQ35000905-1E3DDC1E-8739-4F04-9C31-CFDBED498676Q35019051-F4BE158D-3C84-4911-8974-4C73923F787AQ35024409-2A40708A-9828-4682-BC09-1B18DA14CE3BQ35040559-D03CD095-3CBB-4ED6-BED2-DB84D7A9E988Q35102114-046E5DB4-F84F-4238-81CB-E43196C2F4F4Q35171168-1771B995-BB0E-42CF-BA28-6691B1AC1B40Q35291766-A2A128C8-C169-48F2-81A8-E0C03A975F70Q35505203-6DF25924-E71C-4E51-87E7-2F29995FEF5DQ35564782-CEE33854-D30F-4C7F-81D4-AF8D1E649F35Q35593296-84593734-BC3A-4B17-9848-7EBD5B464E5EQ35659264-65594EBD-9E0C-4A78-8916-484E0734567CQ35743556-23BEE1DA-E77F-4665-85FB-A32B82D87B84Q35744467-28156266-3098-457E-9CBB-CD870739A61FQ35822412-C8631F30-1B78-46C0-8420-AA3C12E824E3Q35859876-6D3D59AE-FCE5-4004-B0B5-178B69A0FD72Q35861519-7B338340-E893-4C0C-BA4C-3E95BEA4DC3D
P2860
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@en
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@nl
type
label
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@en
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@nl
prefLabel
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@en
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@nl
P2093
P1476
Loss of bone mineral density a ...... ent of antiretroviral regimen.
@en
P2093
Barbara A da Silva
Barry M Bernstein
Grace A McComsey
Martin S King
Roula B Qaqish
Todd T Brown
P304
P356
10.1097/QAI.0B013E3181ADCE44
P407
P577
2009-08-01T00:00:00Z